文献速递肿瘤 PET/CT核素与放射性配体治疗

基于谷氨酰脲基的前列腺特异性膜抗原抑制剂:新型低分子量诊疗一体化放射性示踪剂开发过程中的经验教训

Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
PubMed 文献 · J Nucl Med · 2017-01-01

本文回顾了基于谷氨酰脲基的小分子前列腺特异性膜抗原(PSMA)抑制剂放射性配体作为诊疗一体化药物的发展历程,指出该类配体在PSMA阳性前列腺癌的PET/SPECT显像及转移性去势抵抗性前列腺癌的放射性配体治疗中显示高灵敏度和显著反应,多个配体已进入或即将进入前瞻性临床试验,并讨论了配体设计经验与临床需求间的平衡。

要点

  • 小分子PSMA抑制剂放射性配体在PET和SPECT显像中显示高灵敏度,并在转移性去势抵抗性前列腺癌的PSMA放射性配体治疗中显示显著反应。
  • MIP-1404、PSMA-11、DCFPyL、PSMA-617、PSMA-1007等已进入或即将进入前瞻性临床试验。
  • 2013年至2016年PSMA靶向PET显像相关出版物数量从19篇增至218篇。

核心结论

  • 小分子PSMA抑制剂放射性配体的首次人体研究显示对PSMA阳性前列腺癌的高灵敏显像及转移性去势抵抗性前列腺癌的显著治疗反应。
  • 多个PSMA放射性配体已进入或即将进入前瞻性临床试验,但需从基础研究和临床需求角度审视配体设计和临床需求间的平衡。

研究设计与样本

  • 本文为综述,回顾基于谷氨酰脲基的小分子PSMA抑制剂放射性配体的开发经验与临床转化进展。

主要发现

  • PSMA放射性配体的首次人体研究显示PET和SPECT对PSMA阳性前列腺癌显像高度敏感,PSMA放射性配体治疗后转移性去势抵抗性前列腺癌出现显著反应。
  • MIP-1404、PSMA-11、DCFPyL、PSMA-617、PSMA-1007等已进入或即将在多个国家进入前瞻性临床试验。
  • Web of Science检索「PSMA」和「PET」发现2013年仅19篇出版物,2016年为218篇。

局限性

  • 原文提到需要从基础研究角度和临床需求角度进一步审视PSMA放射性配体设计的经验教训及最佳设计与广泛临床需求间的可接受折中是否已达成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In recent years, several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of theranostic radiopharmaceuticals for the treatment of prostate cancer (PC). In the second decade of the 21st century, a new era in nuclear medicine was initiated by the clinical introduction of small-molecule PSMA inhibitor radioligands, 40 y after the clinical introduction of 18F-FDG. Because of the high incidence and mortality of PC, the new PSMA radioligands have already had a remarkable impact on the clinical management of PC. For the continuing clinical development and long-term success of theranostic agents, designing modern prospective clinical trials in theranostic nuclear medicine is essential. First-in-human studies with PSMA radioligands derived from small-molecule PSMA inhibitors showed highly sensitive imaging of PSMA-positive PC by means of PET and SPECT as well as a dramatic response of metastatic castration-resistant PC after PSMA radioligand therapy. This tremendous success logically led to the initiation of prospective clinical trials with several PSMA radioligands. Meanwhile, MIP-1404, PSMA-11, 2-(3-{1-carboxy-5-[(6-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL), PSMA-617, PSMA-1007, and others have entered or will enter prospective clinical trials soon in several countries. The significance becomes apparent by, for example, the considerable increase in the number of publications about PSMA-targeted PET imaging from 2013 to 2016 (e.g., a search of the Web of Science for "PSMA" AND "PET" found only 19 publications in 2013 but 218 in 2016). Closer examination of the initial success of PC treatment with PSMA inhibitor radiotracers leads to several questions from the basic research perspective as well as from the perspective of clinical demands: What lessons have been learned regarding the design of PSMA radioligands that have already been developed? Has an acceptable compromise between optimal PSMA radioligand design and a broad range of clinical demands been reached? Can the lessons learned from multiple successes within the PSMA experience be transferred to further theranostic approaches?

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kopka K, Benešová M, Bařinka C, et al. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. J Nucl Med. 2017. PMID: 28864607. doi:10.2967/jnumed.116.186775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。